Clinical trials: Community Acquired Pneumonia (CAP)
Community-Acquired Pneumonia (CAP), Pneumonia
PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms
In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children…
- Trial name
- PIONEERS (NCT07099976)
- Testing
- The novel care pathway intervention, Usual Care Alone
- Where
- 6 sites in Canada
- Volunteers
- 698 people
- Sponsor
- Jeffrey Pernica
Community-Acquired Pneumonia
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
The study will assess the clinical efficacy at Day 14-21 (Test of Cure), 14-21 days after starting the study drug; those subjects from whom a baseline pathogen is identified will also be assessed for bacteriologic response.
- Trial name
- NCT00140023
- Testing
- Azithromycin microspheres 2.0 single dose
- Where
- 5 sites in Philippines
- Volunteers
- 47 people
- Sponsor
- Pfizer
Community Acquired Pneumonia (CAP)
Clinical Characteristics and Outcome of Patients With Community Acquired Pneumonia
the goal of this observational study is to evaluate the clinical characteristic and outcomes of patients with community-acquired pneumonia admitted to Sohag University Hospital.
- Trial name
- NCT06716099
- Volunteers
- 100 people
- Sponsor
- Sohag University
Asthma (Diagnosis), Community-Acquired Pneumonia (CAP)
Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Questionnaires, Cough Sounds, and Breath Sounds
This study aims to establish a standardized, synchronized data collection system for pediatric symptom questionnaires, cough sounds, and breath sounds, and to construct a multimodal database of pediatric respiratory diseases…
- Trial name
- NCT07613242
- Testing
- Multimodal respiratory data collection
- Where
- China
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Shanghai Children's Medical Center
Community Acquired Pneumonia (CAP)
Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)
The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP).
- Trial name
- NCT06892197
- Testing
- Methylprednisolone (drug), hydrocortisone
- Where
- 14 sites in Denmark
- Volunteers
- 1,600 people
- Sponsor
- Copenhagen Respiratory Research
Community Acquired Pneumonia (CAP)
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive…
- Trial name
- DC-CAP (NCT07537413)
- Testing
- Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily
- Where
- 4 sites in United States
- Volunteers
- 900 people
- Sponsor
- University of Maryland, Baltimore
Angina, Acute Bronchiolitis
Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France…
- Conditions
- Angina, Acute Bronchiolitis, Acute Bronchitis, COPD Exacerbation (AECOPD)
- Trial name
- GRASP (NCT07359287)
- Testing
- Antibiotic prescribing according to guidelines
- Where
- France
- Volunteers
- 4,500 people
- Sponsor
- University Hospital, Caen
Community Acquired Bacterial Pneumonia
Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia
Community-acquired bacterial pneumonia, which is often called CAP, is a bacterial infection in the lungs and is treated with antibiotics. Sometimes people need to be in the hospital to be treated for CAP.
- Trial name
- CAP (NCT01605864)
- Testing
- Efficacy of ceftaroline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Albany Medical College
Community-Acquired Pneumonia
Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Children CAP
Community-Acquired Pneumonia (CAP) of children are a recurrent pathology with multiple severity scores. The etiology is never really identified, and the initial treatment is always based on probabilistic antibiotics, in the case…
- Trial name
- OptiPAC (NCT02668237)
- Testing
- OptiPAC, Usual care
- Where
- 11 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Community-acquired Pneumonia, Severe Pneumonia
Fulminant Severe CAP - an Observational Study
Severe community-acquired pneumonia (CAP) represents a major cause of hospital mortality. Among severe CAP cases, some exhibit a rapidly progressive evolution, leading to severe ARDS/acute respiratory failure and septic shock…
- Conditions
- Community-acquired Pneumonia, Severe Pneumonia, ARDS, Human, Sepsis
- Trial name
- FULMISCAP (NCT06516601)
- Testing
- no intervention
- Where
- 2 sites in Italy
- Volunteers
- 1,460 people
- Sponsor
- University of Trieste
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Community-acquired Pneumonia
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Through a series of retrospective analysis, it is hoped that an objective evaluation of the effect and safety of Eucalyptol, Limonene and Pinene Enteric Soft Capsules in the treatment of community-acquired pneumonia can be made.
- Trial name
- NCT05002192
- Testing
- Eucalyptol, Limonene and Pinene Enteric Soft Capsule, Ambroxol injection, Other oral mucolytic drugs
- Where
- 7 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Grand Johamu Pharmaceutical Company, Ltd.
Community Acquired Respiratory Disease Syndrome
Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
The goal of the study is to determine whether providing early treatment with a glucocorticoid drug, called methylprednisolone, will improve survival in critically ill patients with severe community-acquired pneumonia (CAP).
- Trial name
- ESCAPe (NCT01283009)
- Testing
- Inactive Substance, Methylprednisolone
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 584 people
- Sponsor
- VA Office of Research and Development
Childhood Pneumonia, Mycoplasma Pneumonia
Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)
To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and…
- Conditions
- Childhood Pneumonia, Mycoplasma Pneumonia, Antibody-secreting Cells, Enzyme-linked Immunospot (ELISpot)
- Trial name
- myCAP (NCT03613636)
- Testing
- Enzyme-linked immunospot (ELISpot) assay [Blood]
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Pneumonia, Pediatric Infectious Disorder
Ultrasonographic Air Bronchogram in Pediatric CAP
This study evaluates the prognostic role of the change of arborescent air bronchogram, a typical ultrasonographic finding of lung consolidation due to pneumonia, in the management of pediatric CAP.
- Trial name
- USINCHILD (NCT03556488)
- Testing
- US air bronchogram score
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Catholic University of the Sacred Heart
Community-acquired Pneumonia
Santeon-CAP; Dexamethasone in Community-acquired Pneumonia
The present study is designed to investigate the beneficial effects of adjunctive dexamethasone therapy in patients admitted with community-acquired pneumonia, additionally aiming at assessing what patients benefit from…
- Trial name
- NCT01743755
- Testing
- Dexamethasone
- Where
- 4 sites in Netherlands
- Volunteers
- 413 people
- Sponsor
- St. Antonius Hospital
Community-acquired Pneumonia
PCV13 Impact on Pneumococcal Nasopharyngeal Carriage Study
Prospective, observational, hospital based, nasopharyngeal carriage (NPC), vaccine effectiveness study Comparisons will be made in Filipino children, aged 8 weeks to ≤60 months of age at enrollment, who have been hospitalized…
- Trial name
- IMPACT (NCT05114902)
- Testing
- Nasopharyngeal swab
- Where
- Philippines
- Volunteers
- 451 people
- Sponsor
- Asian Foundation for Tropical Medicine Inc.
Community-acquired Pneumonia (CAP)
TCM Cohort for Elderly CAP
This study evaluates the real-world clinical efficacy of traditional Chinese medicine (TCM) in elderly Community-acquired pneumonia (CAP) patients and explores syndrome characteristics and their associations with biomarkers.
- Trial name
- NCT07797686
- Testing
- Traditional Chinese medicine (TCM), Non-traditional Chinese medicine (non-TCM)
- Where
- China
- Volunteers
- 2,234 people, healthy volunteers welcome
- Sponsor
- Henan University of Traditional Chinese Medicine
Pneumonia, Bacterial
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan.
- Trial name
- NCT01189487
- Testing
- ampicillin sodium/sulbactam sodium
- Where
- 22 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Pfizer
Mild to Moderate, Community-Acquired Pneumonia (CAP)
Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia
The goal of this clinical trial is to learn if NRICM102 (a Traditional Chinese Medicine) works to treat community-acquired pneumonia (CAP) in adults when added to standard antibiotic therapy.
- Conditions
- Mild to Moderate, Community-Acquired Pneumonia (CAP), Antibiotic Therapy, Intravenous
- Trial name
- NCT07583992
- Testing
- NRICM102, Intravenous Antibiotic
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Research Institute of Chinese Medicine, Ministry of Health and Welfare